The elephant in the room is the LOE extension for Lyrica. Earlier in the year we were told September/October time frame. Well, Halloween is this coming Wednesday and still no word. And if anyone thinks the delay in announcing the 2019 OP isn't tied to FDA's decision, you're too stupid to be working here anyway and need to be shown the door. So Sales Management says "stay focused", because they need to wring every last dollar out of patent regardless of the actual date of LOE, and we will find out ... eventually. I would venture to guess there is an OP "A" and an OP "B", depending upon the LOE date. 6 months of revenue from IM's biggest product will impact headcount significantly. C2 has contractual obligations with BMS and C1/3 with ES, so the cuts can only go so deep, but they will be deeper if the FDA passes on the extension. That's just the reality of the situation. The numbers have to work out to ensure the company meets earnings expectations, as Ian's (Albert's) fiduciary responsibility is to shareholders, not employees.
I'd keep your resume up to date and your networking channels active. On the bright side, the severance is generous, VERP (if eligible) would provide 3 years of company health care benefits, and the job market is strong. I'd be OK with being separated involuntarily, and I think pretty much everyone will land on their feet. Best wishes to all, and I hope you get what you want out of the current reorganization.
I'd keep your resume up to date and your networking channels active. On the bright side, the severance is generous, VERP (if eligible) would provide 3 years of company health care benefits, and the job market is strong. I'd be OK with being separated involuntarily, and I think pretty much everyone will land on their feet. Best wishes to all, and I hope you get what you want out of the current reorganization.
